日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

帕博利珠单抗联合比美替尼治疗不可切除的局部晚期或转移性三阴性乳腺癌患者

Chumsri, Saranya; Larson, Joseph J; Liu, Emily; Tenner, Kathleen S; Adams, Daniel; Weidner, Morgan T; Arnold, Amanda N; Haley, Dana L; Advani, Pooja; Sideras, Kostandinos; Moreno-Aspitia, Alvaro; Thompson, E Aubrey; Perez, Edith A; Knutson, Keith L

Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer.

不同的空间免疫微环境与三阴性乳腺癌的预后独立相关

Carter Jodi M, Chumsri Saranya, Hinerfeld Douglas A, Ma Yaohua, Wang Xue, Zahrieh David, Hillman David W, Tenner Kathleen S, Kachergus Jennifer M, Brauer Heather Ann, Warren Sarah E, Henderson David, Shi Ji, Liu Yi, Joensuu Heikki, Lindman Henrik, Leon-Ferre Roberto A, Boughey Judy C, Liu Minetta C, Ingle James N, Kalari Krishna R, Couch Fergus J, Knutson Keith L, Goetz Matthew P, Perez Edith A, Thompson E Aubrey

Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)

卡培他滨和拉帕替尼联合或不联合IMC-A12(西妥昔单抗)治疗既往接受过曲妥珠单抗和化疗的HER2阳性晚期乳腺癌患者的随机II期试验:NCCTG N0733(Alliance)

Haddad, Tufia C; He, Jun; O'Sullivan, Ciara C; Chen, Beiyun; Northfelt, Donald; Dueck, Amylou C; Ballman, Karla V; Tenner, Kathleen S; Linden, Hannah; Sparano, Joseph A; Hopkins, Judith O; De Silva, Chamath; Perez, Edith A; Haluska, Paul; Goetz, Matthew P

Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study.

辅助曲妥珠单抗对随机临床试验中局部区域复发率的影响:北中部癌症治疗组 N9831(联盟)研究

Vargas Carlos E, Thorpe Cameron S, Dueck Amylou C, Tenner Kathleen S, Davidson Nancy E, Martino Silvana, Pisansky Thomas M, Hwang E Shelley, Halyard Michele Y, Pockaj Barbara A, Perez Edith A

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

曲妥珠单抗辅助治疗期间产生的HER2特异性抗体免疫与切除的HER2乳腺癌复发率降低相关

Norton, Nadine; Fox, Nicholas; McCarl, Christie-Ann; Tenner, Kathleen S; Ballman, Karla; Erskine, Courtney L; Necela, Brian M; Northfelt, Donald; Tan, Winston W; Calfa, Carmen; Pegram, Mark; Colon-Otero, Gerardo; Perez, Edith A; Clynes, Raphael; Knutson, Keith L

Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial

NCCTG(Alliance)N9831试验中HER2阳性Breaty st肿瘤的内在亚型和治疗反应

Perez, Edith A; Ballman, Karla V; Mashadi-Hossein, Afshin; Tenner, Kathleen S; Kachergus, Jennifer M; Norton, Nadine; Necela, Brian M; Carr, Jennifer M; Ferree, Sean; Perou, Charles M; Baehner, Frederick; Cheang, Maggie Chon U; Thompson, E Aubrey

Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain

接受曲妥珠单抗联合化疗的HER2阳性乳腺癌患者生存期延长与宿主针对HER2胞内结构域的抗体免疫有关。

Knutson, Keith L; Clynes, Raphael; Shreeder, Barath; Yeramian, Patrick; Kemp, Kathleen P; Ballman, Karla; Tenner, Kathleen S; Erskine, Courtney L; Norton, Nadine; Northfelt, Donald; Tan, Winston; Calfa, Carmen; Pegram, Mark; Mittendorf, Elizabeth A; Perez, Edith A

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial

基因组分析显示,免疫功能基因与北中部癌症治疗组n9831辅助曲妥珠单抗试验的临床结果密切相关。

Perez, Edith A; Thompson, E Aubrey; Ballman, Karla V; Anderson, S Keith; Asmann, Yan W; Kalari, Krishna R; Eckel-Passow, Jeanette E; Dueck, Amylou C; Tenner, Kathleen S; Jen, Jin; Fan, Jian-Bing; Geiger, Xochiquetzal J; McCullough, Ann E; Chen, Beiyun; Jenkins, Robert B; Sledge, George W; Winer, Eric P; Gralow, Julie R; Reinholz, Monica M

Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831

接受化疗(含或不含曲妥珠单抗)的 HER2 阳性乳腺癌患者体内可溶性人表皮生长因子受体 2 (HER2) 水平:来自北美中部癌症治疗组辅助治疗试验 N9831 的结果

Moreno-Aspitia, Alvaro; Hillman, David W; Dyar, Stephen H; Tenner, Kathleen S; Gralow, Julie; Kaufman, Peter A; Davidson, Nancy E; Lafky, Jacqueline M; Reinholz, Monica M; Lingle, Wilma L; Kutteh, Leila A; Carney, Walter P; Dueck, Amylou C; Perez, Edith A

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer

RC0639:紫杉醇、曲妥珠单抗和拉帕替尼作为早期HER2阳性乳腺癌辅助治疗的II期研究

Moreno-Aspitia, Alvaro; Dueck, Amylou C; Ghanem-Cañete, Ismael; Patel, Tejal; Dakhil, Shaker; Johnson, David; Franco, Sandra; Kahanic, Stephen; Colon-Otero, Gerardo; Tenner, Kathleen S; Rodeheffer, Richard; McCullough, Ann E; Jenkins, Robert B; Palmieri, Frances M; Northfelt, Donald; Perez, Edith A